Literature DB >> 16103047

The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective.

Thomas R Geiger1, Daniel S Peeper.   

Abstract

Resistance to anoikis ("detachment-induced apoptosis") has been suggested to be a prerequisite for cancer cells to metastasize. In a functional screen for suppressors of anoikis, we identified the neurotrophic receptor TrkB. Upon s.c. inoculation in mice, TrkB-expressing cells formed highly invasive and metastatic tumors. Here, we discuss our findings within the context of the proposed role of TrkB in human malignancies and address the question of its feasibility as a target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103047     DOI: 10.1158/0008-5472.CAN-05-0709

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells.

Authors:  Yuen-Keng Ng; Elaine Yue Ling Wong; Cecilia Pik Yuk Lau; Jessica Pui Lan Chan; Sze Chuen Cesar Wong; Andrew Sai-Kit Chan; Maggie Pui Chun Kwan; Sai-Wah Tsao; Chi-Man Tsang; Paul Bo San Lai; Anthony Tak Cheung Chan; Vivian Wai Yan Lui
Journal:  Invest New Drugs       Date:  2010-08-07       Impact factor: 3.850

2.  A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

Authors:  Junegoo Lee; Tilahun Jiffar; Michael E Kupferman
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

3.  Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

Authors:  M Cazorla; J M Arrang; J Prémont
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Authors:  Christophe J Desmet; Tristan Gallenne; Alexandre Prieur; Fabien Reyal; Nils L Visser; Ben S Wittner; Marjon A Smit; Thomas R Geiger; Jamila Laoukili; Sedef Iskit; Boris Rodenko; Wilbert Zwart; Bastiaan Evers; Hugo Horlings; Abderrahrim Ajouaou; John Zevenhoven; Martin van Vliet; Sridhar Ramaswamy; Lodewyk F A Wessels; Daniel S Peeper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-12       Impact factor: 11.205

5.  Up-regulation of Tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations.

Authors:  Zhiyong Zhang; Lihui Han; Yugang Liu; Xiaohong Liang; Wensheng Sun
Journal:  Mol Biol Rep       Date:  2008-07-02       Impact factor: 2.316

Review 6.  Cancer invasion and metastasis: interacting ecosystems.

Authors:  Marc Mareel; Maria J Oliveira; Indira Madani
Journal:  Virchows Arch       Date:  2009-05-27       Impact factor: 4.064

7.  Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma.

Authors:  Sanjeev A Vasudevan; Xiaoying Shang; Xiaoyi Shang; Shirong Chang; Ningling Ge; Jose L Diaz-Miron; Heidi V Russell; M John Hicks; Andrew D Ludwig; Catherine L Wesson; Susan M Burlingame; Eugene S Kim; Javed Khan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 8.  Metastasis: recent discoveries and novel treatment strategies.

Authors:  Suzanne A Eccles; Danny R Welch
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

9.  Elevated p21-activated kinase 2 activity results in anchorage-independent growth and resistance to anticancer drug-induced cell death.

Authors:  Jerry W Marlin; Andrew Eaton; Gerald T Montano; Yu-Wen E Chang; Rolf Jakobi
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

10.  A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis.

Authors:  Marjon A Smit; Thomas R Geiger; Ji-Ying Song; Inna Gitelman; Daniel S Peeper
Journal:  Mol Cell Biol       Date:  2009-05-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.